StockNews.AI
LTRN
StockNews.AI
64 days

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

1. LTRN reported positive results from a clinical trial on lung cancer treatment. 2. A patient showed durable complete response using LP-300 in advanced NSCLC.

2m saved
Insight
Article

FAQ

Why Very Bullish?

Positive clinical results can drive investor confidence and share price, similar to past biotech successes.

How important is it?

Promising clinical trial results indicate potential for future approvals, crucial for LTRN's growth.

Why Short Term?

Market reaction to clinical trial results typically occurs quickly, as seen in other biotech stocks.

Related Companies

AXGTCRTXKURA
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announces remarkable clinical observations for a patient in Lantern's Phase 2 HARMONIC™ clinical trial. A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) has achieved a durable complete response in their target cancer lesions following treatment with LP-300 in combination with standard-o.

Related News